Ravi M Patel1, Kanecia Zimmerman2, David P Carlton3, Reese Clark4, Daniel K Benjamin5, P Brian Smith2. 1. Emory University School of Medicine, Atlanta, GA; Children's Healthcare of Atlanta, Atlanta, GA. Electronic address: rmpatel@emory.edu. 2. Duke University, Durham, NC. 3. Emory University School of Medicine, Atlanta, GA; Children's Healthcare of Atlanta, Atlanta, GA. 4. Pediatrix Medical Group, Greenville, SC. 5. Clemson University, Clemson, SC.
Abstract
OBJECTIVE: To test the hypothesis that early caffeine treatment on the day of birth, compared with later treatment in very low birth weight (VLBW, <1500 g) infants receiving continuous positive airway pressure (CPAP) therapy, is associated with a decreased risk of CPAP failure in the first week of life. STUDY DESIGN: Multicenter, observational cohort study in 366 US neonatal intensive care units. We evaluated inborn, VLBW infants discharged from 2000 to 2014, who received only CPAP therapy without surfactant treatment on day of life (DOL) 0, had a 5-minute Apgar ≥3, and received caffeine in the first week of life. We used multivariable conditional logistic regression to compare the risk of CPAP failure, defined as invasive mechanical ventilation or surfactant therapy on DOL 1-6, by timing of caffeine treatment as either early (initiation on DOL 0) or routine (initiation on DOL 1-6). RESULTS: We identified 11 133 infants; 4528 (41%) received early caffeine and 6605 (59%) received routine caffeine. Median gestational age was lower in the early caffeine group, 29 weeks (25th, 75th percentiles; 28, 30) vs the routine caffeine group, 30 weeks (29, 31); P < 0.001. The incidence of CPAP failure on DOL 1-6 was similar between the early and routine caffeine groups: 22% vs 21%; adjusted OR = 1.05 (95% CI: 0.93, 1.18). CONCLUSIONS: Early caffeine treatment on the day of birth was not associated with a decreased risk of CPAP failure in the first week of life for VLBW infants initially treated with CPAP.
OBJECTIVE: To test the hypothesis that early caffeine treatment on the day of birth, compared with later treatment in very low birth weight (VLBW, <1500 g) infants receiving continuous positive airway pressure (CPAP) therapy, is associated with a decreased risk of CPAP failure in the first week of life. STUDY DESIGN: Multicenter, observational cohort study in 366 US neonatal intensive care units. We evaluated inborn, VLBW infants discharged from 2000 to 2014, who received only CPAP therapy without surfactant treatment on day of life (DOL) 0, had a 5-minute Apgar ≥3, and received caffeine in the first week of life. We used multivariable conditional logistic regression to compare the risk of CPAP failure, defined as invasive mechanical ventilation or surfactant therapy on DOL 1-6, by timing of caffeine treatment as either early (initiation on DOL 0) or routine (initiation on DOL 1-6). RESULTS: We identified 11 133 infants; 4528 (41%) received early caffeine and 6605 (59%) received routine caffeine. Median gestational age was lower in the early caffeine group, 29 weeks (25th, 75th percentiles; 28, 30) vs the routine caffeine group, 30 weeks (29, 31); P < 0.001. The incidence of CPAP failure on DOL 1-6 was similar between the early and routine caffeine groups: 22% vs 21%; adjusted OR = 1.05 (95% CI: 0.93, 1.18). CONCLUSIONS: Early caffeine treatment on the day of birth was not associated with a decreased risk of CPAP failure in the first week of life for VLBW infants initially treated with CPAP.
Authors: Dalal Taha; Sharon Kirkby; Ursula Nawab; Kevin C Dysart; Linda Genen; Jay S Greenspan; Zubair H Aghai Journal: J Matern Fetal Neonatal Med Date: 2014-02-17
Authors: Barbara Schmidt; Robin S Roberts; Peter Davis; Lex W Doyle; Keith J Barrington; Arne Ohlsson; Alfonso Solimano; Win Tin Journal: N Engl J Med Date: 2007-11-08 Impact factor: 91.245
Authors: Peter G Davis; Barbara Schmidt; Robin S Roberts; Lex W Doyle; Elizabeth Asztalos; Ross Haslam; Sunil Sinha; Win Tin Journal: J Pediatr Date: 2009-11-18 Impact factor: 4.406
Authors: Janneke Dekker; Stuart B Hooper; Jeroen J van Vonderen; Ruben S G M Witlox; Enrico Lopriore; Arjan B Te Pas Journal: Pediatr Res Date: 2017-05-17 Impact factor: 3.756
Authors: Fernando R Moya; Jan Mazela; Paul M Shore; Steven G Simonson; Robert Segal; Phillip D Simmons; Timothy J Gregory; Carlos G Guardia; Judy R Varga; Neil N Finer Journal: BMC Pediatr Date: 2019-05-11 Impact factor: 2.125
Authors: Laura Moschino; Sanja Zivanovic; Caroline Hartley; Daniele Trevisanuto; Eugenio Baraldi; Charles Christoph Roehr Journal: ERJ Open Res Date: 2020-03-02